Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods

• Status: Unknown status
• Trial end date: 2018-06-30
• Target enrollment: 0
• Participant gender: All

Summary

REDEMPTION (Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods) is observing and collating the treatment course, safety profile, and outcomes of patients around the world who are choosing to self import generic versions of the Direct Acting Antivirals Sofosbuvir, Ledipasvir and Daclatasvir from countries like China, India and Bangladesh.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: FixHepC
• Treatments: Ledipasvir; Sofosbuvir; Velpatasvir

Criteria

Inclusion Criteria:

Quantitative HCV RNA > 100

Exclusion Criteria:

Contraindications to DAA medications